Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5907241 | 0.98 | HRH3 (0.48) | HRH3HRH4ALDH1A1KDM4ECHRNB2 | |
| SCHEMBL26098964 | 0.83 | SIGMAR1 (0.52) | HRH3TDP1 | |
| SCHEMBL2462684 | 0.83 | SCN9A (0.38) | HRH3CHRNB2CHRNA4CHEK1 | |
| SCHEMBL27955520 | 0.81 | CYP1A2 (0.51) | HRH3CYP2D6TDP1 | |
| SCHEMBL5737465 | 0.81 | ALDH1A1 (0.49) | ALDH1A1KDM4ETDP1 | |
| SCHEMBL23747331 | 0.81 | MC4R (0.50) | HRH3ALDH1A1KDM4E | |
| SCHEMBL5740200 | 0.81 | CHEK1 (0.51) | HRH3ALDH1A1KDM4ECHEK1 | |
| SCHEMBL26546814 | 0.78 | KDM4E (0.42) | HRH3ALDH1A1KDM4ETDP1 | |
| SCHEMBL28258991 | 0.77 | LTA4H (0.46) | HRH3HRH4 | |
| SCHEMBL18097762 | 0.75 | SCN9A (0.41) | CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240245670-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | NOVARTIS AG (CH) | 2024-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245670-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | IKZF1, IKZF2, IKZF3 | HRH3 4782/4885HRH4 4184/4885ALDH1A1 2942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.